Evidence map›Paper›PMID 38029107›Full record

ArticleFrontiers in microbiology2023

Evaluation of cholesterol transformation abilities and probiotic properties of

Zhili He, Tinghui Wang, Shichang Zhang, Kuojiang Shi, Fan Wang, Yanzhao Li, Chanqing Lin, Jianguo Chen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Next-Generation Probiotics in Allergy Therapy: Scientific Evidence and Clinical Applications.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026
    Review
  5. Frontiers in microbiology · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhili He *Beijing YuGen Pharmaceutical Co., Ltd., Beijing, China.
Tinghui Wang *Beijing YuGen Pharmaceutical Co., Ltd., Beijing, China.
Shichang ZhangBeijing YuGen Pharmaceutical Co., Ltd., Beijing, China.
Kuojiang ShiBeijing YuGen Pharmaceutical Co., Ltd., Beijing, China.
Fan WangBeijing YuGen Pharmaceutical Co., Ltd., Beijing, China.
Yanzhao LiBeijing Hotgen Biotechnology Inc., Beijing, China.
Chanqing LinBeijing Hotgen Biotechnology Inc., Beijing, China.
Jianguo ChenBeijing YuGen Pharmaceutical Co., Ltd., Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypercholesterolemia, a risk factor for cardiovascular disease (CVD), often requires therapeutic agents with varying degrees of side effects. This has created a need for safe and natural alternatives such as medications or functional foods that can improve lipid metabolism and reduce cholesterol levels. In recent years, Next-generation probiotics (NGPs) have recently emerged as a potential solution, offering distinct mechanisms compared to traditional probiotics. Among the NGPs,

Indexed as

B. dorei YGMCC0564bile saltcholesterolnext-generation probioticsshort-chain fatty acids

Identifiers

PMID38029107
PMCPMC10666794
OpenAlexW4388617971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.